Literature DB >> 14688589

Appropriate antibiotic use and why it is important: the challenges of bacterial resistance.

Jay M Lieberman1.   

Abstract

After the introduction of antibiotics in the mid-20th century, clinicians soon witnessed clinical failures secondary to bacterial resistance. Despite scientists' efforts to synthesize more potent antibiotics during the last five decades, bacterial resistance continues to evolve, in large part because of the overuse and misuse of antibiotics. The treatment of several pathogens, including methicillin-resistant Staphylococcus aureus, penicillin-resistant Streptococcus pneumoniae and vancomycin-resistant enterococci, is problematic. New solutions are needed to preserve the activity of our current antibiotic armamentarium, to lower the overall risk of bacterial resistance and to successfully treat patients with resistant bacterial infections. Options include: development of new antibiotics to treat resistant organisms; vaccination to prevent infections; and improved use of antibiotics. Because bacteria will eventually develop means to avoid being killed by antibiotics, judicious use of antibiotics by all clinicians is imperative. Appropriate antibiotic use involves selection of a "targeted spectrum" antibiotic, as well as an appropriate dose and duration.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14688589     DOI: 10.1097/01.inf.0000101851.57263.63

Source DB:  PubMed          Journal:  Pediatr Infect Dis J        ISSN: 0891-3668            Impact factor:   2.129


  27 in total

Review 1.  Antibiotic resistance in pediatric urology.

Authors:  Rachel S Edlin; Hillary L Copp
Journal:  Ther Adv Urol       Date:  2014-04

2.  Impact of implementing French antibiotic guidelines for acute respiratory-tract infections in a paediatric emergency department, 2005-2009.

Authors:  F Angoulvant; D Skurnik; H Bellanger; H Abdoul; X Bellettre; L Morin; M Aptecar; G Galli-Gibertini; O Bourdon; C Doit; A Faye; J-C Mercier; R Cohen; C Alberti
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2011-10-16       Impact factor: 3.267

Review 3.  Macrolide-resistant Streptococcus pneumoniae: clinical implications for the empiric treatment of community-acquired respiratory tract infections.

Authors:  Stephen Brunton; Paul Iannini
Journal:  MedGenMed       Date:  2005-12-07

Review 4.  Vaccination greatly reduces disease, disability, death and inequity worldwide.

Authors:  F E Andre; R Booy; H L Bock; J Clemens; S K Datta; T J John; B W Lee; S Lolekha; H Peltola; T A Ruff; M Santosham; H J Schmitt
Journal:  Bull World Health Organ       Date:  2008-02       Impact factor: 9.408

Review 5.  Quorum Sensing of Periodontal Pathogens.

Authors:  Darije Plančak; Larisa Musić; Ivan Puhar
Journal:  Acta Stomatol Croat       Date:  2015-09

6.  Multisite exploration of clinical decision making for antibiotic use by emergency medicine providers using quantitative and qualitative methods.

Authors:  Larissa May; Glencora Gudger; Paige Armstrong; Gillian Brooks; Pamela Hinds; Rahul Bhat; Gregory J Moran; Lisa Schwartz; Sara E Cosgrove; Eili Y Klein; Richard E Rothman; Cynthia Rand
Journal:  Infect Control Hosp Epidemiol       Date:  2014-07-23       Impact factor: 3.254

7.  National ambulatory antibiotic prescribing patterns for pediatric urinary tract infection, 1998-2007.

Authors:  Hillary L Copp; Daniel J Shapiro; Adam L Hersh
Journal:  Pediatrics       Date:  2011-05-09       Impact factor: 7.124

8.  Payment analysis of two diagnosis and management approaches of acute otitis media.

Authors:  Janet R Casey; Michael E Pichichero
Journal:  Clin Pediatr (Phila)       Date:  2014-05-09       Impact factor: 1.168

9.  Antibiotic prescription rates for acute respiratory tract infections in US ambulatory settings.

Authors:  Carlos G Grijalva; J Pekka Nuorti; Marie R Griffin
Journal:  JAMA       Date:  2009-08-19       Impact factor: 56.272

10.  Azithromycin use in paediatrics: A practical overview.

Authors:  Philippe Ovetchkine; Michael J Rieder
Journal:  Paediatr Child Health       Date:  2013-06       Impact factor: 2.253

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.